Company Description
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye.
The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.
It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery.
In addition, the company sells injector parts, and other related instruments and devices.
It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.
The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally.
STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Country | United States |
IPO Date | Feb 24, 1992 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 1,056 |
CEO | Thomas G. Frinzi |
Contact Details
Address: 25651 Atlantic Ocean Drive Lake Forest, California United States | |
Website | https://www.staar.com |
Stock Details
Ticker Symbol | STAA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000718937 |
CUSIP Number | 852312305 |
ISIN Number | US8523123052 |
Employer ID | 95-3797439 |
SIC Code | 3851 |
Key Executives
Name | Position |
---|---|
Thomas G. Frinzi | President, Chief Executive Officer & Chairman |
Dr. Keith Holliday Ph.D. | Chief Technology Officer |
Nancy Sabin | Chief Marketing Officer |
Patrick F. Williams | Chief Financial Officer |
Warren Foust | Chief Operating Officer |
Brian Moore | Vice President of Investor Relations & Corporate Development |
Dr. Magda Michna Ph.D. | Chief Clinical, Regulatory & Medical Affairs Officer |
Dr. Scott D. Barnes M.D. | Chief Medical Officer |
James Francese | Senior Vice President of Commercial Operations - North America & APAC |
Nathaniel B. Sisitsky Esq. | General Counsel & Corporate Secretary |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Oct 31, 2024 | 8-K/A | [Amend] Current Report |
Oct 30, 2024 | 10-Q | Quarterly Report |
Oct 30, 2024 | 8-K | Current Report |
Oct 18, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Sep 06, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Aug 19, 2024 | 4 | Filing |
Aug 07, 2024 | 10-Q | Quarterly Report |
Aug 07, 2024 | 8-K | Current Report |
Jun 24, 2024 | 4 | Filing |